BCAL Diagnostics Limited (BDX) Fair Value & Analysis
Healthcare · AU · Market cap A$27.3M
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from A$0.0800 to A$0.0235 (−70.6%) since Jun 24, 2026. Share price −2.5% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0540 – A$0.1402 · the A$0.0810 price screens above the A$0.0235 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BCAL Diagnostics Limited (BDX) currently trades at A$0.0810, while our model-based Fair Value estimate is A$0.0235 — implying the stock looks roughly 71.0% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$2.5M. Revenue declined 8.1% year over year. The balance sheet holds a net cash position of A$2.1M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
BCAL Diagnostics Limited reported revenue of A$21.6K in FY2024 versus A$275K in FY2020, a compound −47.0%/yr. Reported net income was −A$7.2M in FY2024.
Open the full interactive analysis →
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $472.80 | $190.31 | -60% |
| Danaher Corporation DHR | $186.64 | $85.95 | -54% |
| WuXi AppTec Co WUXAY | $18.59 | $25.09 | +35% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $63.74 | $25.98 | -59% |
| Agilent Technologies, Inc A | $138.37 | $65.93 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BCAL Diagnostics Limited (BDX) undervalued?
What is the fair value of BDX?
What is the quality score of BDX?
What is the revenue of BCAL Diagnostics Limited (BDX)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.